Cocaine abuse has been associated with vasculitis and stroke, and is suspected to in¯uence the progression of AIDS dementia. Cocaine may enhance HIV-1 neuroinvasion by actions directed at the blood-brain barrier. HIV-1 appears to penetrate the human brain microvascular endothelial cell barrier by a paracellular route breached by tumor necrosis factor-a (TNF-a). Cocaine's effects on the blood-brain barrier were investigated using human brain microvascular endothelial cells and peripheral blood monocytes. Cocaine (10 75 M and 10 76 M) increased molecular permeability of the barrier and viral invasion by the macrophage-tropic HIV-1 JR ± FL into the brain chamber. Cocaine also augmented apoptosis of brain endothelial cells and monocytes, increased secretion of four chemokines (interleukin-8, interferon-inducible protein-10, macrophage in¯ammatory protein-1a, and monocyte chemoattractant protein-1) and the cytokine, TNF-a, by human monocytes. TNF-a enhanced invasion of the brain compartment by macrophage-tropic, lymphotropic, and bitropic HIV-1 strains. These data indicate that HIV-1 neuroinvasion can be increased by (a) cocaine's direct effects on brain microvascular endothelial cells and (b) paracrine effects of cocaine-induced pro-in¯ammatory cytokines and chemokines on the blood-brain barrier.
Introduction
Immunological consequences of cocaine abuse on the blood-brain barrier (BBB) are poorly understood, but appear signi®cant since cocaine abuse is associated with vasculitis (Mody et al, 1988; Daras et al, 1994) , suggesting an enhancement in leukocyte migration through endothelial barriers. Cocaine abuse is also accompanied by changes detected by brain imaging, indicating a defect in the BBB (Holman et al, 1992; Strickland et al, 1993) . Cocaine may induce brain damage by its toxicity to neurons, as shown in vitro by synergy with HIV-1 (Koutsilieri et al, 1997) , and by enhancement of HIV-1 replication in mononuclear cells (Bagasra and Pomerantz, 1993) . The importance of drug abuse in the AIDS epidemic is highlighted by a recent report noting the history of drug abuse in a majority of HIV-1 infected persons, including those with HIV-1 encephalitis who were autopsied by the Medical Examiner of New York City (Kibayashi et al, 1996) . However, epidemiological studies of cocaine's role in AIDS dementia have produced highly variable results in different populations (Bacellar et al, 1994; Wellman, 1992; Handelsman et al, 1992) . This discrepancy may, in part, be a re¯ection of the variability of cocaine's immunomodulating effects on induction of pro-in¯amma-tory cytokines and chemokines (Fiala et al, 1996a) .
Our previous work indicated that: (a) in cocaineaddicted individuals, cocaine infusion has divergent effects of secretion of pro-in¯ammatory cytokines, which appear to be heterogeneous for mononuclear cells from different donors, with inhibitory effects seen in macrophages and stimu-latory effects in lymphocytes, and (b) tumor necrosis factor-a (TNF-a) increases HIV-1 penetration across a human BBB model (Fiala et al, 1996a) . We have recently shown that in vivo cocaine infusion stimulates secretion of interferon-g (IFNg), and probably TNF-a, in mononuclear cells of a majority of addicted subjects (Gan X-H et al, 1998 (manuscript submitted)), and have demonstrated that TNF-a does indeed increase HIV-1 penetration across a human BBB model . We have also shown that cocaine enhances monocyte migration across human brain microvascular endothelial cells (BMVEC) in the BBB model. These effects of cocaine appear to be mediated by increased expression of cell adhesion molecules (Gan X-H et al, 1998 (manuscript submitted)). Taken together, the data suggest that cocaine may increase HIV-1 neuroinvasion by its effect on migration of virus-infected monoyctes, and by induction of TNF-a and other pro-in¯ammatory cytokines which can open the blood-brain barrier to cell-free virus. The data presented in this report demonstrate cocaine's stimulatory effects on apoptosis of brain endothelial cells and monocytes, and on induction of chemokines and pro-in¯ammatory cytokines, such as TNF-a, which can modify the integrity of the BBB and increase HIV-1 neuroinvasion.
Results
We have shown that cocaine can induce adhesion molecules, and enhance transendothelial migration of leukocytes (Gan X-H et al, 1998 (manuscript submitted)), which may disturb the function of the BBB. The in vivo effects of cocaine on the BBB could also be mediated by cocaine's direct actions on endothelial cells, and by paracrine responses to cytokines induced by cocaine. We have, therefore, investigated cocaine's effects on endothelial cell permeability and apoptosis as well as cocaine's induction of chemokines and cytokines.
Cocaine's enhancement of endothelial permeability Experiments in the in vitro BBB model demonstrated that cocaine has direct effects on BMVEC permeability. Treatment of the BBB model with cocaine (10 75 M to 10 76 M) resulted in a signi®cant dose-dependent increase in permeability to both inulin and dextran ( Figure 1 ).
Cocaine's induction of apoptosis Cocaine has previously been reported to induce apoptosis of thymocytes (Wu et al, 1997) . We examined cocaine's induction of apoptosis in cultures of BMVEC and in monocytes using an enzyme-linked immunosorbent assay (ELISA) of generated nucleosomes. As shown in Figure 2 , cocaine induced apoptosis in both cell types in a dose-dependent fashion. The effect of 10 75 M cocaine on apoptosis of monocytes was comparable to that seen following an anti-FAS antibody response.
Cocaine's enhancement of chemokine secretion by monocytes In preliminary experiments, we showed, in the BBB model, that the chemokines normally expressed and secreted by T-cells upon activation, RANTES, interleukin-8 (IL-8) and macrophage in¯ammatory protein-2 (MIP-2), strongly attract monocyte transmigration into the lower chamber of the model, and increase ionic permeability. Medium containing MIP-2 (50 ng/ml), a chemokine previously shown to cause a severe breach in the BBB (Bell et al, 1996) , decreased electrical resistance in the model by 35%. We have now examined cocaine's induction of two C-X-C chemokines, IL-8 and interferoninducible protein-10 (IP-10), and two C-C chemokines, macrophage in¯ammatory protein-1a (MIP1a) and monocyte chemoattractant protein-1 (MCP-1), which were shown to be chemoactive in the murine central nervous system (Bell et al, 1996) .
Cocaine (10 79 M ± 10 76 M) induced secretion of the two C-X-C chemokines, IP-10 and IL-8, and the two C-C chemokines, MIP-1a and MCP-1, into the supernatant of 48-h monocyte cultures, while higher cocaine concentrations (10 75 M ± 10 74 M) inhibited secretion, so as to produce a bell-shaped doseresponse pro®le (Figure 3 ). However, using monocytes from two other donors, cocaine was found to up-regulate MIP-1a, MCP-1, IP-10 and IL-8 secretion at the higher cocaine concentrations (10 74 M ± 10 75 M) (data not shown).
Cocaine's enhancement of TNF-a secretion by monocytes TNF-a plays a crucial role in AIDS dementia by stimulating HIV-1 expression in microglia (Chao et al, 1994) and macrophages (Poli and Fauci, 1992) , reactivating HIV-1 infection in astrocytes (Fiala et al, 1996b) , inducing astrocytosis (Wilt et al, 1995) and damaging the BBB. The effects of cocaine in HIV dementia may be mediated, in part, through TNF-a. Cocaine treatment of monocytes increased secretion of TNF-a in a dose-responsive fashion (10 75 M ± 10 79 M) and potentiated the effects of LPS Figure 3 Cocaines effects on C-X-C chemokines (IL-8 and IP-10) and C-C chemokines (MIP-a and MCP-1) secretion by peripheral blood monocytes. Monocytes (400 000), suspended in RPMI 1640 with 10% autologous serum with or without cocaine at the indicated concentration, were incubated for 48 h. The supernatant medium was collected and stored frozen until the ELISA assay as described in Materials and methods. The results are expressed in pg/ml. 
Enhancement of HIV-1 penetration across human BMVEC by TNF-a or cocaine
Previously, using the in vitro BBB model, we showed that the HIV-1 JR ± FL strain penetrates the BMVEC/astrocyte bilayer via a paracellular route opened by TNF-a . The effect of TNF-a is dose-dependent without an apparent threshold in the range of 1 ± 100 ng/ml. The signi®cance of this ®nding to human disease could be substantial if it is also found to occur with other HIV-1 strains. We, therefore, examined the effects of TNF-a on HIV-1 invasion in the BBB model using four different HIV-1 strains. Without treatment, the model functioned as a tight barrier against HIV-1, retaining approximately 99.5% of the viral RNA copies for 24 h. TNF-a treatment enhanced the penetration of all strains tested: JR-FL, a monocytotropic strain, increased 5.6-fold; ADA, a monocytotropic strain, increased 2.2-fold; a 5.9-fold increase was seen with the 89.6, a dual-tropic strain; and IIIB, a lymphotropic strain, increased 3.8-fold (Table 1) .
Cocaine (10 75 M) treatment alone enhanced penetration of the HIV JR ± FL strain into the brain chamber up to 8.4-fold when replicate BBB models were treated for 24 h or 48 h (Table 2) .
Discussion
Route of HIV-1 invasion across the human BMVEC/ astrocyte barrier Our experiments in the human BBB model are designed to experimentally study possible routes and molecular mechanisms of HIV-1 invasion across the BBB, and the role of factors, such as Figure 4 Effect of cocaine on TNF-a secretion by peripheral blood monocytes. Peripheral monocytes (400 000) from two donors were incubated in RPMI 1640 medium with 5% fetal calf serum for 24 h in the presence of various concentrations of cocaine or LPS. At the completion of the incubation, TNF-a concentration in the supernatant medium was determined by the ELISA assay as described in Materials and methods. cocaine, in AIDS. Early after the primary HIV-1 infection, the individual's plasma contains enormous concentrations of cell-free HIV-1 (Piatak et al, 1993) . HIV-1 RNA levels in the cerebrospinal uid (CSF) appear to correlate with those in the plasma (Ellis et al, 1997; McArthur et al, 1997; Roberston et al, 1998) . This relationship, however, was observed by Ellis et al. (1997) in subjects with CD4+ counts 4200/mm 3 , whereas McArther et al (1997) found this correlation in those with counts 5200/mm 3 , and Roberston et al (1998) noted this correlation in patients at various stages of HIV disease. The role of HIV-1-infected CD4+ lymphocytes in the pathogenesis of early HIV-1 encephalitis (Massari et al, 1990 ) is supported by early stagespeci®c lymphocytic pleocytosis (McArthur et al, 1989; Elovara et al, 1988) and perivascular lymphocytic in®ltrates in the brain (Gray et al, 1992) . The virus in the CSF of the subjects examined by Ellis et al (1997) was, however, cell-free virus. A previous study also noted that HIV-1 isolated from the CSF was found in the supernatant rather than in the cellular fraction (Spector et al, 1993) suggesting that the CSF/plasma relationship is attributable to cellfree virus, and might be indirectly related to lymphocytic pleocytosis.
As demonstrated previously and herein, cell-free macrophage-, lympho-and bi-tropic HIV-1 strains can penetrate across an in vitro endothelial barrier using a route opened by TNF-a. This response to TNF-a is speci®c to human endothelial cells, speci®cally tight brain microvascular endothelial cells. Other endothelial cells present a weaker barrier to HIV-1 penetration, and astrocytes present no signi®cant barrier to penetration . Most viral isolates in early infection are macrophage-tropic; yet our human BMVEC were not susceptible to infection with a macrophagetropic HIV-1 JR ± FL strain . Other investigators have shown HIV-1 infection of human BMVEC, but only by lymphotropic strains (Moses et al, 1993) . These observations would argue against HIV-1 infection of BMVEC as a mechanism of early neuroinvasion analogous to the simian immunode®ciency virus (SIV) infection of the simian brain endothelial cells (Edinger et al, 1997) . Nevertheless, using a combination of in situ DNA polymerase reaction, reverse transcriptase-initiated in situ PCR and immunohistochemistry, HIV-1 mRNA expression was demonstrated within microvascular endothelial and choroid plexus cells in the brain from AIDS dementia patients (Bagasra et al, 1996) , suggesting that the endothelial cells can be infected by lymphotropic strains in neuro-AIDS.
The paracellular route opened by TNF-a and possibly cocaine for cell-free plasma virus could be of considerable signi®cance for HIV-1 neuroinvasion in early HIV-1 disease. Additionally, lymphocytes could be major participants in early neuroinvasion, indirectly mediating an opening in the BBB during lymphocyte migration, which could be augmented by cocaine's enhancement of the transendothelial migration of leukocytes (Gan X-H et al, 1998 (manuscript submitted)). In late HIV-1 disease, in patients with AIDS dementia, the`Trojan horse' transport of HIV-1 by monocytes and T lymphocytes is believed to be the major route of neuroinvasion (Gendelman et al, 1997) , which could also be augmented by cocaine. These different mechanisms may overlap in successive stages of AIDS, as re¯ected by a gradual increase in immune stimulation noted in the CSF (Gissle Ân et al, 1994) .
Role of cocaine in cell-free HIV-1 invasion across the human BMVEC barrier Similar to TNF-a, cocaine was shown to increase HIV-1 penetration across the BBB model. Cocaine's effects on the BBB appear complex including both direct, pro-apoptotic effects on endothelial cells, and indirect effects mediated by chemokines and cytokines. Although the relative signi®cance of these molecular mechanisms for HIV-1 neuroinvasion is not established, TNF-a may play a critical role in cocaine's actions since it was shown to open the BBB for all macrophage-tropic, T-cell-tropic and bi-tropic HIV-1 strains. In addition, cocaine's direct effects on BMVEC may help to clear the way for HIV-1 JR ± FL penetration.
Role of chemokines induced by cocaine and chemokine receptors in HIV-1 invasion Cocaine stimulates human monocytes to secrete chemokines, some of which breach the BBB in vivo, as demonstrated by horseradish peroxidase staining (Bell et al, 1996) . The potential role of chemokine receptors in retroviral neuroinvasion has recently produced considerable interest. SIV infection of simian brain endothelial cells was shown to be mediated via a chemokine receptor CCR5-dependent mechanism, which was inhibited by the CCR5 ligand, RANTES (Edinger et al, 1997) . The C-C chemokines, RANTES, MIP-1a, and MIP-1b, were initially hailed as potential therapeutic agents for AIDS (Cocchi et al, 1995) . Their role, however, appears to be cell-type dependent-inhibitory to primary strains in T lymphocytes and stimulatory in macrophages (Schmidtmayerova et al, 1996) . The major physiological role for the chemokines is as participants in the in¯ammatory response, aiding leukocyte traf®cking across the vascular wall. The part that chemokines play in HIV-1 neuroinvasion may, therefore, be a double-edged sword. Chemokines could block chemokine receptors, which are putative HIV co-receptors, on brain endothelial cells, but they could also open the BBB to HIV-1 invasion.
Cocaine is considered a signi®cant co-factor in AIDS, but its mechanisms are poorly understood. Since cocaine was shown to induce monocytic secretion of two C-X-C and two C-C chemokines, as well as TNF-a, and inasmuch as chemokines can breach the BBB in vivo, as shown by horseradish peroxidase staining (Bell et al, 1996) , it seems likely that cocaine can have a signi®cant impact on HIV-1 neuroinvasion.
Materials and methods
Chemicals (7)-cocaine was provided by the Research Triangle Institute (Research Triangle Park, NC, USA) through the Research Technology Branch of the National Institute on Drug Abuse, and was found to be negative (less than 10 pg/ml) for endotoxin by the Limulus Lysate Test (Sigma, St. Louis, MO, USA).
Cell culture and peripheral blood monocytes
The human blood-brain barrier model was constructed using adult human brain microvascular endothelial cells and human astrocytes on opposite sides of a porous Cyclopore membrane coated with collagen I and ®bronectin (Collaborative Biomedical Products, Bedford, MA, USA) and cultured in DME/F12 (Irvine Scienti®c, Santa Ana, CA, USA), with 10% fetal calf serum and endothelial cell growth supplement (Upstate Biotechnology, Lake Placid, NY, USA) as described previously. Human brain microvascular endothelial cells were prepared from adult cortical tissues obtained during surgery .
Human monocytes were separated from the elutriated peripheral blood of leukopheresed healthy volunteers who had provided informed consent under a protocol approved by the Institutional Review Board. The mononuclear cells were subsequently passed through a continuous Percol gradient to enrich for CD14 + , CD3 7 , CD56 + , CD19 + mononuclear cells. The monocyte preparations were greater than 90% monocytes¯ow cytometry. Monocytes by were cultured in RPMI 1640 with 10% autologous serum with or without cocaine for 48 h for the chemokine assays, or for 24 h for the TNF-a assay. At the endpoints, the medium was separated by brief centrifugation and frozen at 7708C until the ELISA assay was performed.
Virus strains HIV-1 strains were classi®ed on the basis of their use of chemokine receptors as proposed recently (Berger et al, 1998) . The following HIV-1 strains were used: HIV JR ± FL , a monocytotropic R5 (Deng et al, 1996) , R3 (He et al, 1997) and STRL33 (Liao et al, 1997) strains (1.06610 11 RNA copies/ml); ADA, a monocytotropic R5 (Deng et al, 1996) , R3 (He et al, 1997) and STRL33 (Liao et al, 1997) strains (1.26610 11 RNA copies/ml); 89.6, a dual-tropic X4, R2b, R3, R5 (Doranz et al, 1996) ,and STRL33 (Liao et al, 1997) strain (2610 11 RNA copies/ml); and IIIB, a T-cell tropic X4 virus (Feng et al, 1996) (1.56610 10 RNA copies/ml). HIV JR ± FL stock was prepared in human cord umbilical cells, as described previously , whereas the other strains were grown in normal human donor PBMC at the UCSD Center for AIDS Research.
HIV-1 RNA assay HIV-1 RNA was quantitated in supernatants diluted 1 : 4 with PBS, using the Amplicor HIV Monitor Test, performed according to the manufacturer's suggested procedure .
Apoptosis assay
Apoptosis quantitation was performed using the Nucleosome ELISA kit (Oncogene Research Products, Cambridge, MA, USA) which quantitates mono-and oligo-nucleosomes in treated cells by DNA af®nity-mediated capture of free nucleosomes, followed by ELISA detection of the histone component. As positive controls, cells treated with anti-FAS antibody or phorbol-12-myristate-13-acetate (10 mg/ml) (Calbiochem) with phytohemagglutinin A (50 ng/ml) were assayed. The extracts for ELISA testing were prepared by cell centrifugation at 1000 r.p.m. (2006g), followed by resuspension of the cell pellet in lysis buffer. Sample diluent was added to the ®nal concentration of 1610 6 cells/ml, and the cells were incubated for 30 min on ice, centrifuged at 3000 r.p.m. (15006g) for 10 min at 48C, and the resulting lysate was frozen at 7208C. The Nucleosome ELISA was performed according to the manufacturer's instructions, and the Nucleosome standards (10, 3.3, 1.1 and 0.366 U/ml) were run with each assay. The quantitation of nucleosomes was expressed in nucleosome units (One unit=number of nucleosomes from 444 UV-treated Daudi cells/ml). ELISA for chemokines and TNF-a Human MIP-1a, MCP-1, IL-8, IP-10 and TNF-a levels were determined using Quantikine ELISA kits (R&D Systems, Minneapolis, MN, USA), following the manufacturer's instructions.
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